Alzheimer's disease
Anti-amyloid, anti-tau, and next-gen disease modifiers after the first wave of approvals.
Lenses
EarlierApproval →
LLYApprovedcash ok
2026-09-30 (48d)Company-guided
Kisunla (donanemab) · NCT04437511 · Broader access update
BIIBApprovedcash ok
2026-10-20 (68d)Company-guided
Leqembi franchise · NCT03887455 · Subcutaneous / label update
AVXLPh3cash ok
2026-12-15 (124d)Estimated
Blarcamesine · NCT03790709 · Regulatory filing decision
ANVSPh3cash ok
2027-02-01 (172d)Estimated
Buntanetap · NCT05686044 · Phase 3 readout